There is now abundant evidence that treatment with angiotensin-converting enzyme inhibitors (ACE-I) ameliorates the progression of chronic renal disease. Attention has therefore focused on the role of the renin angiotensin-aldosterone (RAA) system in mediating the development of progressive glomerulosclerosis and angiotensin II (Ang II) has been implicated in several processes thought to be important in the pathogenesis of this entity. Conversely, ACE is also known to catalyse the breakdown of bradykinin. Thus, ACE-I treatment results in elevated bradykinin levels which may cause selective efferent arteriolar dilatation, suggesting an alternative explanation for the beneficial effects of this class of drugs in chronic renal disease. The development of specific angiotensin type 1 receptor antagonists (AT 1 RA) has provided a means of testing the relative
Introduction
Evidence that blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors (ACE-I) significantly attenuates the development of proteinuria and progressive glomerulosclerosis in experimental models of reduced renal mass 1 and diabetes mellitus, 2 provided the first indications that the course of human chronic renal disease could be altered by drug therapy. Further studies showed that the renal protective effects of ACE-I were associated with their ability to normalise glomerular capillary pressure through efferent arteriolar dilatation, a property not shared by other antihypertensives producing equivalent control of systemic hypertension. 3 Clinical studies using ACE-I have confirmed significant renal protection in type 1 and type 2 diabetes, 4, 5 and in progressive chronic renal disease due to a variety of causes. 6 These dramatic findings have focused attention on the role of the renin-angiotensin-aldosterone (RAA) system in the pathogenesis of progressive glomerulosclerosis. Although plasma renin concentrations are lower in rats subjected to 5/6 nephrectomy than in normal controls, 1 it has been shown that local activity of the RAA sys- importance of these two mechanisms. In addition, AT 1 RAs differ from ACE-I in their effect on the RAA system in other aspects which may represent therapeutic advantages. This paper reviews studies which have compared ACE-I and AT 1 RAs in several rat models of chronic renal disease. Most have found similar beneficial effects including amelioration of proteinuria and glomerulosclerosis, which suggests that the effects of ACE-I are due to a reduction in Ang II activity and not due to increased levels of bradykinin. One long-term study has suggested greater renal protection with candesartan than with enalapril. However, conclusions as regards the relative efficacy of these two groups of agents in ameliorating the progression of chronic renal disease await the results of further long-term studies.
tem may be increased without affecting circulating renin levels. 
Angiotensin II as an effector in progressive glomerulosclerosis
In vivo and in vitro experiments have shown angiotensin II (Ang II) to be the central effector in several of the pathogenetic mechanisms involved progressive glomerulosclerosis. Micropuncture studies in rats after subcutaneous infusion of Ang II for 8 weeks showed significant glomerular capillary hypertension that was associated with more albuminuria and glomerulosclerosis than in controls. 8 Nonhaemodynamic effects of Ang II have also been described. In isolated perfused kidney, Ang II infusion caused loss of glomerular size permselectivity and proteinuria; an effect that could be completely prevented by pretreatment with an angiotensin type I receptor antagonist (AT 1 RA). 9 In mesangial cell culture experiments, the addition of Ang II to the culture medium results in increased growth 10 and induction of transforming growth factor-␤ (TGF-␤) with resultant stimulation of matrix protein synthesis. 11 Nevertheless, pharmacodynamic studies of ACE-I have shown effects on other hormonal systems, including the kallikrein-kinin system. Thus ACE, also termed kininase II, is responsible for the break-down of bradykinin, and ACE inhibition results in elevated bradykinin levels. 12, 13 In several experimental models, evidence suggests that elevated kinins are responsible for at least some of the effects of ACE-I. Neointima formation after balloon injury to the carotid artery is inhibited by ACE-I, but the effect is lost in animals cotreated with a kinin receptor antagonist.
14 Similarly, in an animal model of cardiac failure, the combination of bradykinin receptor blockade with ACE inhibition significantly reduces the benefit of the latter. 15 Evidence regarding the role of bradykinin in the effect of ACE-I on renal disease is conflicting. In rats with passive Heymann nephritis, treatment with a kinin receptor antagonist prevented the antiproteinuric effect of enalapril. 16 Furthermore, the reduction in glomerular capillary pressure produced by an ACE-I has been shown to be significantly inhibited by treatment with a kinin receptor antagonist. 17 Conversely, long-term coadministration of a kinin receptor blocker did not decrease the beneficial effects of an ACE-I after 5/6 nephrectomy.
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Pharmacodynamics of ACE-I vs AT 1 RA
The development of compounds that selectively block angiotensin subtype 1 receptors has made it possible to inhibit the RAA system at a level distal to ACE. Although both ACE-I and AT 1 RA are effective in inhibiting the RAA system, they differ significantly in their effects on the components of the system. While ACE inhibition results in reduced levels of Ang II and elevated levels of renin and bradykinin, 19 AT 1 RA produces elevations in both renin and Ang II, and has no effect on bradykinin.
12 These differences may represent significant advantages of AT 1 RA over ACE-I in two respects.
Firstly, ACE-Is are able to block only ACE-dependent Ang II production, while AT 1 RA blocks the effect of Ang II from any source at the receptor level. In the presence of ACE inhibition, studies have shown that Ang II may be produced by other proteases, including chymase and leukocyte-derived cathepsin G. Indeed, disruption of the ACE gene in mice results in normal intrarenal levels of Ang II. 20 Chymase has been found in several organs, although levels of chymase were almost undetectable in the kidney. 21, 22 However, the relevance of these findings to the efficacy of ACE-I is unknown.
Secondly, it is now known that there are at least two subtypes of the angiotensin receptor. Thus blockade of AT 1 receptors can be expected to result in stimulation of AT 2 receptors by elevated Ang II levels. AT 1 receptors mediate most of the known effects of Ang II, including vasoconstriction, stimulation of aldosterone synthesis and release, and renal tubular sodium and water reabsorption. AT 2 receptors do not appear to be involved in any of these functions, although they may control pressurenatriuresis. 23 However, experimental evidence suggests that they may counterbalance some of the effects mediated by AT 1 receptors. In cell culture, mesangial cells treated with an AT 2 receptor antagonist display enhanced proliferation and reduced apoptosis in response to Ang II. 24 Furthermore, vascular smooth muscles transfected with an AT 2 receptor expression vector attenuate neointimal proliferation after balloon injury. 25 Disruption of the AT 2 receptor gene in mice results in a significant increase in blood pressure and an enhanced pressor response to exogenous Ang II. 26 Thus, stimulation of AT 2 receptors may produce antiproliferative and antihypertensive effects that are expected to be beneficial in the context of chronic renal disease. In a rat model of cardiac failure, the importance of AT 2 receptor stimulation has been shown by the finding that administration of an AT 2 R antagonist blocks the cardioprotective effect of AT 1 RA.
15
ACE-I vs AT 1 RA in rat models of chronic renal disease
To evaluate the significance of these theoretical considerations, at least 14 studies have directly compared the effects of ACE-I and AT 1 RA in different experimental models of progressive chronic renal disease (Table 1); 27-40 similar findings have been noted by S Kato (unpublished data, March 1998).
5/6 Nephrectomy
The first study in this well-established model of secondary focal and segmental glomerulosclerosis by Lafayette et al 27 compared the effects of the ACE-I enalapril, the AT 1 RA losartan, and combination antihypertensive therapy with hydralazine, reserpine, and hydrochlorothiazide, commencing 2 weeks after surgery. After 19 weeks of therapy and equivalent blood pressure control in all treatment groups, animals in both the ACE-I and AT 1 RA groups had significantly less proteinuria than did untreated controls and combination antihypertensive-treated rats. Similarly, histologic analysis of the remnant kidney showed significant and equal protection in the ACE-I and AT 1 RA groups.
Micropuncture studies showed a similar reduction in glomerular transcapillary hydraulic pressure with losartan and enalapril, indicating that renal protection was achieved by the same mechanism. 27 Subsequent studies in the same model have confirmed these findings using different agents. [28] [29] [30] [31] [32] [33] In addition, Kakinuma et al 28 found similar degrees of protection from arterial wall thickening with ACE-I and AT 1 RA. Ots et al 33 compared treatment with either losartan or enalapril to combination therapy-all treatment groups showed significant amelioration of proteinuria and glomerulosclerosis, and there was no additional benefit attributable to combination therapy. In addition, the authors found a positive correlation between systolic blood pressure and percentage glomerulosclerosis, and concluded that the renal protective effects of the two agents were similar and were closely related to the degree to which they controlled systemic hypertension.
In an attempt to separate the effects of these two groups of agents, Noda et al 32 used a more severe model of renal injury by delaying the start of therapy for 15 weeks after surgery. After 16 weeks of therapy, rats treated with enalapril or candesartan 
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SBP, systolic blood pressure; Rx, treatment; U pr V: urinary protein excretion; Enal: enalapril 110 mg/l (n = 27); Cand: candesartan 50 mg/l (n = 30).
showed similar protection from increasing proteinuria. However, while both groups developed less glomerulosclerosis than did untreated controls, only the degree of protection in the candesartan group was statistically significant. Our laboratory has recently completed a similar study, in which rats were treated with either enalapril or candesartan, starting 5 weeks after 5/6 nephrectomy. Results showed similar effects on blood pressure control, proteinuria, and glomerulosclerosis among the enalapril and candesartan treatments ( Table 2) . When compared to historic controls, both treatments retarded the rise in proteinuria such that levels at 24 weeks were similar to those previously seen in untreated rats at 12 weeks (104 mg/d). 41 In addition, glomerulosclerosis at 24 weeks was similar to that shown in untreated controls at 12 weeks (42% glomerulosclerosis).
41
Hypertensive nephrosclerosis AT 1 RA have been compared to ACE-I in several models of hypertensive renal disease. Ziai et al 34 studied fawn-hooded hypertensive rats that spontaneously develop hypertension and chronic renal failure. Uninephrectomy was performed to accelerate the development of glomerulosclerosis, and rats received either enalapril or irbesartan. An equivalent degree of blood pressure control was achieved in the treatment groups and the degree of protection from glomerulosclerosis was similar. As seen in the 5/6 nephrectomy model, both treatments produced a reduction in glomerular capillary pressure. In the two-kidney, one-clip model of hypertension, treatment with enalapril or losartan resulted in reduced albuminuria and similar protection from early glomerulosclerosis. 35 Treatment with irbesartan in spontaneously hypertensive rats subjected to uninephrectomy resulted in less reduction in proteinuria than with enalapril treatment. However, these results are difficult to interpret, as the mean arterial pressure was 30 mm Hg lower in the latter group. The percentage of glomerulosclerosis was similar between groups. 36 
Other models
Other models in which the comparative effects of ACE-I and AT 1 RA have been studied include passive Heymann nephritis 38 (which is a model of chronic renal disease resulting from immunologic injury), spontaneous age-related glomerulosclerosis in Mü nich Wistar Fromter (MWF/Ztm) rats, 38 spontaneous glomerulosclerosis in hyperlipidaemic Imai rats, 39 and chronic allograft nephropathy. 40 As seen in Table 1 , ACE-I and AT 1 RA produced similar beneficial effects in each of these models. In addition, our laboratory has recently completed a study comparing enalapril with candesartan therapy in streptozotocin-induced diabetes. Both treatments prevented the development of proteinuria, which is a reliable predictor of diabetic nephropathy. Interestingly, both drugs also suppressed the increase in glomerular expression of mRNA for MCP-1 and the associated infiltration by macrophages seen in untreated controls (S Kato, unpublished data, March 1998).
Conclusion
Despite differences in their effects on the RAA system, data suggests that ACE-I and AT 1 RA are equally effective in preventing glomerular capillary hypertension and ameliorating the progression of chronic renal disease. This, in turn, implies that their effects are due primarily to the inhibition of the action of Ang II at the AT 1 R. The elevated bradykinin levels, resulting from ACE inhibition or the AT 2 R stimulation associated with AT 1 RA, do not appear to play a major role in their renal protective effects. However, it should be noted that the majority of studies reviewed here are of a design more suited to testing the effectiveness of treatment vs no treatment, and may therefore fail to show the differences between two effective therapies. It is interesting that the one study that compared responses to therapy started late (15 weeks) after 5/6 nephrectomy found differences favoring AT 1 RA. Further long-term studies in models of severe chronic injury may therefore be necessary to show the differences between these groups of agents. In addition, studies using bradykinin receptor antagonists and AT 2 RA may provide valuable data on the importance of these components in the amelioration of progressive chronic renal disease.
